Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
May 23, 2024 17:09 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, May 23, 2024 (GLOBE NEWSWIRE) -- Results will be presented at American Society of Clinical Oncology (ASCO) Annual MeetingMedian overall survival was 20.3 months, nearly doubling the...
Brain Cancer Canada awards The Dwayne Andrews Glioblastoma Grant for Research to a study on the impact of anesthetics on brain cancer proliferation
May 08, 2024 08:45 ET
|
Brain Cancer Canada
Brain Cancer Canada grants $80k to study impact of anesthetics on brain tumor growth, led by Dr. Sujoy Banik.
Wistar Scientists Discover New Immunosuppressive Mechanism in Brain Cancer
May 03, 2024 11:32 ET
|
The Wistar Institute
PHILADELPHIA, PA, May 03, 2024 (GLOBE NEWSWIRE) -- The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma — a serious and often...
ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
April 23, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University...
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
March 07, 2024 07:30 ET
|
Mustang Bio, Inc.
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in...
Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial
November 17, 2023 08:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a Phase 0/2 trial of niraparib in patients with newly...
invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
November 09, 2023 05:30 ET
|
invIOs GmbH
Preclinical study will be conducted by Dr. David Reardon’s research groupImmune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer VIENNA, Austria and BOSTON,...
Ivy Center Announces First Patient Treated in Targeted Phase 0/1 Clinical Trial for High-Grade Glioma
November 06, 2023 10:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced the first patient has been treated in a novel Phase 0/1 clinical trial of...
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
October 26, 2023 09:00 ET
|
Mustang Bio, Inc.
MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data...
Ivy Brain Tumor Center Announces Results of Phase 0/1 Study in Recurrent Glioblastoma Patients at the European Society for Medical Oncology (ESMO) 2023 Congress
October 18, 2023 02:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced initial results from a Phase 0/1 clinical trial of the Ataxia telangiectasia...